Filing Details
- Accession Number:
- 0001567619-21-011452
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-06-01 18:01:04
- Reporting Period:
- 2021-05-28
- Accepted Time:
- 2021-06-01 18:01:04
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1389046 | F James Polewaczyk | One Idexx Drive Westbrook ME 04092 | Executive Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-05-28 | 10,000 | $67.85 | 29,915 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-05-28 | 1,039 | $558.89 | 28,876 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-05-28 | 1,370 | $559.77 | 27,506 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-05-28 | 1,274 | $560.79 | 26,232 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-05-28 | 1,429 | $561.77 | 24,803 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-05-28 | 2,462 | $562.65 | 22,341 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-05-28 | 1,713 | $564.04 | 20,628 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-05-28 | 513 | $564.73 | 20,115 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-05-28 | 200 | $565.56 | 19,915 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right-to-buy) | Disposition | 2021-05-28 | 10,000 | $0.00 | 10,000 | $67.85 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 2,627 | 2026-02-13 | No | 4 | M | Direct |
Footnotes
- Includes 12 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2021.
- Represents the weighted average price of the shares sold ranging from a low of $558.22 to a high of $559.22 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $559.23 to a high of $560.22 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $560.24 to a high of $561.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $561.25 to a high of $562.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $562.26 to a high of $563.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $563.36 to a high of $564.33 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $564.38 to a high of $564.88 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $565.42 to a high of $565.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Grant of option to buy 12,627 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2017.
- Not applicable.
Billionaire Hedge Funds
